Magazine Article | September 1, 2021

What Biopharmas Need To Know About Genetic Data Privacy

Source: Life Science Leader

By Roshni Ghosh, Ph.D. And Keith Noe

Recent advances in genome sequencing technology have attracted the interest of biopharmaceutical companies for the development of personalized medicine or therapeutics for potentially “untreatable” diseases. Ever-expanding databases from large-scale biological experiments, clinical trials, genetic records of individuals from DTC genetic-testing companies, and medical records from patients participating in data collection have enabled computational inference akin to real-world biomedical research.

Such approaches may also enable companies to design more effective treatments for diseases such as cancer, hypercholesterelomia, and diabetes.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader